EQS-News : Relief, NeuroRx and Quantum Leap -2-

information about Big Rock and NeuroRx once such documents are filed with 
the SEC, through the website maintained by the SEC at http://www.sec.gov. 
 
*ADDITIONAL INFORMATION POSTED TO WEBSITE* 
 
Big Rock will post information regarding the proposed transaction promptly 
at www.bigrockpartners.com. An investor presentation has been furnished by 
Big Rock to the SEC on a current report on Form 8-K, which can be viewed at 
the SEC's website at www.sec.gov and www.bigrockpartners.com. Big Rock 
intends to use its website as additional means of disclosing information to 
investors, the media, and others interested in Big Rock. It is possible that 
certain information that Big Rock posts to its website could be deemed 
material information, and Big Rock encourages investors, the media, and 
others interested in Big Rock to review the business and financial 
information that Big Rock posts on its website as such information could be 
deemed to be material information. 
 
*PARTICIPANTS IN THE SOLICITATION * 
 
Big Rock, NeuroRx and EarlyBirdCapital and their respective directors and 
executive officers, under SEC rules, may be deemed to be participants in the 
solicitation of proxies of Big Rock's shareholders in connection with the 
proposed transaction. Investors and securityholders may obtain more detailed 
information regarding the names and interests in the proposed transaction of 
Big Rock's directors and officers in Big Rock's filings with the SEC, 
including the forthcoming proxy statement/consent solicitation 
statement/prospectus statement. You may obtain a free copy of these 
documents as described in the preceding paragraph. 
 
*NO OFFER OR SOLICITATION* 
 
This communication shall neither constitute an offer to sell or the 
solicitation of an offer to buy any securities, nor shall there be any sale 
of securities in any jurisdiction in which the offer, solicitation or sale 
would be unlawful prior to the registration or qualification under the 
securities laws of any such jurisdiction. 
 
*CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS* 
 
Neither Big Rock, NeuroRx nor any of their respective affiliates makes any 
representation or warranty as to the accuracy or completeness of the 
information contained in this press release. This press release is not 
intended to be all-inclusive or to contain all the information that a person 
may desire in considering the proposed transaction discussed herein. It is 
not intended to form the basis of any investment decision or any other 
decision in respect of the proposed transaction. 
 
This press release includes "forward-looking statements" within the meaning 
of the federal securities laws with respect to the proposed transaction 
between NeuroRx, Inc. and Big Rock, including statements regarding the 
benefits of the transaction, the anticipated timing of the transaction, the 
drugs under development by NeuroRx and the markets in which it operates. Big 
Rock's and NeuroRx's actual results may differ from its expectations, 
estimates and projections and consequently, you should not rely on these 
forward-looking statements as predictions of future events. These 
forward-looking statements generally are identified by the words "aspire," 
"expect," "estimate," "project," "budget," "forecast," "anticipate," 
"intend," "plan," "may," "will," "will be," "will continue," "will likely 
result," "could," "should," "believe(s)," "predicts," "potential," 
"continue," "future," "opportunity," "strategy," and similar expressions are 
intended to identify such forward-looking statements. These forward-looking 
statements include, without limitation, Big Rock's and NeuroRx's 
expectations with respect to future performance and anticipated financial 
impacts of the proposed transaction. 
 
These forward-looking statements involve significant risks and uncertainties 
that could cause the actual results to differ materially from the expected 
results. Most of these factors are outside Big Rock's and NeuroRx's control 
and are difficult to predict. Factors that may cause such differences 
include, but are not limited to: (1) the approvals, timing, and ability to 
complete the proposed business combination, which may adversely affect the 
trading price of Big Rock's securities; (2) Big Rock's ability to remain 
listed on the Nasdaq Capital Market prior to the closing of the proposed 
business combination; (3) the combined company's continued listing on the 
NASDAQ Capital Market after closing of the proposed business combination; 
(4) the benefits of the proposed business combination, including future 
financial and operating results of the combined company; (5) the inherent 
uncertainty associated with the FDA approval process; (6) the risk that the 
proposed transaction disrupts current plans and operations of NeuroRx as a 
result of the announcement and consummation of the transaction described 
therein and herein; (7) costs related to the proposed business combination; 
(8) changes in applicable laws or regulations; (9) the possibility that the 
combined company may be adversely affected by other economic, business, 
and/or competitive factors; (10) the impact of COVID-19 or other adverse 
public health developments; and (11) other risks and uncertainties that will 
be detailed in the proxy statement/consent solicitation statement/prospectus 
and registration statement to be filed on Form S-4 with the SEC and as 
indicated from time to time in Big Rock's filings with the SEC. These 
filings identify and address other important risks and uncertainties that 
could cause actual events and results to differ materially from those 
contained in the forward-looking statements. 
 
Big Rock and NeuroRx caution that the foregoing list of factors is not 
exclusive. Big Rock and NeuroRx caution readers not to place undue reliance 
upon any forward-looking statements, which speak only as of the date made. 
Neither Big Rock nor NeuroRx undertake or accept any obligation or 
undertaking to release publicly any updates or revisions to any 
forward-looking statements to reflect any change in its expectations or any 
change in events, conditions or circumstances on which any such statement is 
based. 
 
*CORPORATE CONTACTS:                 *NeuroRx, Inc.* 
RELIEF THERAPEUTICS Holding AG*      Jonathan C. Javitt, M.D., 
Raghuram (Ram) Selvaraju, Ph.D., MBA MPH 
Chairman of the Board                Chairman and Chief 
Mail: [e-mail] Executive Officer 
www.relieftherapeutics.com           Mail: [e-mail] 
*MEDIA CONTACTS: 
Relief (Europe)*                     *NeuroRx (United States)* 
MC Services AG                       David Schull 
Anne Hennecke / Brittney Sojeva      Russo Partners, LLC 
Tel.: [phone]         Tel.: [phone] 
Mail: [e-mail] [4]      Mail: 
                                     david.schull@russopartnersl 
                                     lc.com 
*INVESTOR RELATIONS:                 *NeuroRx (United States)* 
Relief (Europe)*                     Brian Korb 
MC Services AG                       Solebury Trout 
Anne Hennecke / Brittney Sojeva      Tel.: [phone] 
Tel.: [phone]         Mail: [e-mail] 
Mail: [e-mail] [4] 
 
Disclaimer: This communication expressly or implicitly contains certain 
forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, 
NeuroRx, Inc. and their businesses. The results reported herein may or may 
not be indicative of the results of future and larger clinical trials for 
RLF-100(TM) for the treatment of COVID-19. Such statements involve certain 
known and unknown risks, uncertainties and other factors, which could cause 
the actual results, financial condition, performance or achievements of 
RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially 
different from any future results, performance or achievements expressed or 
implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG 
is providing this communication as of this date and does not undertake to 
update any forward-looking statements contained herein as a result of new 
information, future events or otherwise. 
 
End of Media Release 
Language:    English 
Company:     RELIEF THERAPEUTICS Holdings AG 
             Avenue de Sécheron 15 
             1202 Genève 
             Switzerland 
E-mail:      [e-mail] 
Internet:    https://relieftherapeutics.com 
ISIN:        CH0100191136 
Listed:      SIX Swiss Exchange 
EQS News ID: 1159544 
 
End of News EQS Group News Service 
 
1159544 2021-01-11 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=32e19337fb8372f473f88c68c33392a1&application_id=1159544&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=c3a197313ba8f5061cb652518d8a708e&application_id=1159544&site_id=vwd&application_name=news 
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=e30303c841a044416d184730bebe9fb7&application_id=1159544&site_id=vwd&application_name=news 
4: mailto:[e-mail] 
 

(END) Dow Jones Newswires

January 11, 2021 01:00 ET (06:00 GMT)